Literature DB >> 27095247

Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995-2012.

Paul Farah1, Rachel Blanda2, Courtney Kromer3, Quinn T Ostrom4,5, Carol Kruchko5, Jill S Barnholtz-Sloan6,7.   

Abstract

General population-based survival statistics for primary malignant brain or other central nervous system (CNS) tumors do not provide accurate estimations of prognosis for individuals who have survived for a significant period of time. For these persons, the use of conditional survival percentages provides more accurate information to estimate potential outcomes. Using information from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program from 1995 to 2012, conditional survival percentages were calculated for 1 or 5 years of additional survival for all primary malignant brain and CNS tumors overall and by gender, race, ethnicity and age. Rates were calculated to include 1, 2, 3, 4, 5, 10 and 15 years post diagnosis. Conditional survival was also calculated in intervals from 1995-2004 to 2005-2012, to examine the potential effect that the introduction of new treatment protocols may have had on survival rates. The percentage of patients surviving one or five additional years varied by histology, age at diagnosis, gender, race and ethnicity. Younger persons (age <15 years at diagnosis) had higher conditional survival percentages for all histologies as compared to all histologies in older patients (age ≥15 years at diagnosis). The longer the amount of time post-diagnosis of a malignant brain or other CNS tumor, the higher the conditional survival. Younger persons at diagnosis had the highest conditional survival irrespective of histology. Use of conditional survival rates provides relevant additional information for patients and their families, as well as for clinicians and researchers, and helps with understanding prognosis.

Entities:  

Keywords:  Brain tumors; Conditional survival; Glioblastoma; Meningioma

Mesh:

Year:  2016        PMID: 27095247     DOI: 10.1007/s11060-016-2127-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  Understanding the Hispanic paradox.

Authors:  L Franzini; J C Ribble; A M Keddie
Journal:  Ethn Dis       Date:  2001       Impact factor: 1.847

2.  Surgery for primary supratentorial brain tumors in the United States, 2000-2009: effect of provider and hospital caseload on complication rates.

Authors:  Victoria T Trinh; Jason M Davies; Mitchel S Berger
Journal:  J Neurosurg       Date:  2014-11-14       Impact factor: 5.115

3.  Survival of European patients with central nervous system tumors.

Authors:  Milena Sant; Pamela Minicozzi; Susanna Lagorio; Tom Børge Johannesen; Rafael Marcos-Gragera; Silvia Francisci
Journal:  Int J Cancer       Date:  2011-11-10       Impact factor: 7.396

4.  Does extent of resection impact survival in patients bearing glioblastoma?

Authors:  Nicolas Dea; Marie-Pierre Fournier-Gosselin; David Mathieu; Philippe Goffaux; David Fortin
Journal:  Can J Neurol Sci       Date:  2012-09       Impact factor: 2.104

Review 5.  Assessment and treatment relevance in elderly glioblastoma patients.

Authors:  Luc Bauchet; Sonia Zouaoui; Amélie Darlix; Nicolas Menjot de Champfleur; Ernestine Ferreira; Michel Fabbro; Christine Kerr; Luc Taillandier
Journal:  Neuro Oncol       Date:  2014-05-02       Impact factor: 12.300

6.  Meningioma grading: an analysis of histologic parameters.

Authors:  A Perry; S L Stafford; B W Scheithauer; V J Suman; C M Lohse
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

7.  Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988-2004.

Authors:  William T Curry; Bob S Carter; Fred G Barker
Journal:  Neurosurgery       Date:  2010-03       Impact factor: 4.654

Review 8.  The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme.

Authors:  Naoki Shinojima; Masato Kochi; Jun-ichiro Hamada; Hideo Nakamura; Shigetoshi Yano; Keishi Makino; Hiromasa Tsuiki; Kenji Tada; Jun-ichi Kuratsu; Yasuji Ishimaru; Yukitaka Ushio
Journal:  J Neurosurg       Date:  2004-08       Impact factor: 5.115

9.  Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.

Authors:  Florian Ringel; Haiko Pape; Michael Sabel; Dietmar Krex; Hans Christoph Bock; Martin Misch; Astrid Weyerbrock; Thomas Westermaier; Christian Senft; Philippe Schucht; Bernhard Meyer; Matthias Simon
Journal:  Neuro Oncol       Date:  2015-08-04       Impact factor: 12.300

10.  Conditional probability of long-term survival in glioblastoma: a population-based analysis.

Authors:  Derek R Johnson; Daniel J Ma; Jan C Buckner; Julie E Hammack
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

View more
  8 in total

Review 1.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

2.  Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008.

Authors:  Y Yuan; J Ross; Q Shi; F G Davis
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

Review 3.  From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.

Authors:  A Zygogianni; M Protopapa; A Kougioumtzopoulou; F Simopoulou; S Nikoloudi; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2018-01-15       Impact factor: 3.405

Review 4.  The effect of race on the prognosis of the glioblastoma patient: a brief review.

Authors:  Nitesh P Patel; Kristopher A Lyon; Jason H Huang
Journal:  Neurol Res       Date:  2019-07-04       Impact factor: 2.448

5.  Effects of Copper Reduction on Angiogenesis-Related Factorszzm321990in Recurrent Glioblastoma Cases

Authors:  Shima Jazayeri; Alireza Feli; Mohammad Ali Bitaraf; Masoud Solaymani Dodaran; Mazdak Alikhani; Mohammad Javad Hosseinzadeh-Attar
Journal:  Asian Pac J Cancer Prev       Date:  2016-10-01

6.  The association between race and survival in glioblastoma patients in the US: A retrospective cohort study.

Authors:  Andrew Bohn; Alexander Braley; Pura Rodriguez de la Vega; Juan Carlos Zevallos; Noël C Barengo
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

7.  Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

Authors:  Gregory F Guzauskas; Marc Salzberg; Bruce Cm Wang
Journal:  CNS Oncol       Date:  2018-08-20

8.  Inequalities in Meningioma Survival: Results from the National Cancer Database.

Authors:  Andrew I Yang; Kobina G Mensah-Brown; Cole Rinehart; Ramie Fathy; Frederick L Hitti; Jason Brant; John Y K Lee
Journal:  Cureus       Date:  2020-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.